TCGA-AR-A24U-01A-11R-A169-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 104
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- INFLAMMATORY_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.490
- INTERFERON_GAMMA_RESPONSE+0.460
- TNFA_SIGNALING_VIA_NFKB+0.460
- COMPLEMENT+0.440
- IL2_STAT5_SIGNALING+0.440
- MTORC1_SIGNALING+0.420
- CHOLESTEROL_HOMEOSTASIS+0.410
- PROTEIN_SECRETION+0.410
Top 10 suppressed
- DNA_REPAIR-0.290
- ESTROGEN_RESPONSE_EARLY-0.220
- ESTROGEN_RESPONSE_LATE-0.220
- WNT_BETA_CATENIN_SIGNALING-0.210
- KRAS_SIGNALING_DN-0.170
- NOTCH_SIGNALING-0.140
- PANCREAS_BETA_CELLS-0.100
- MYOGENESIS-0.070
- MYC_TARGETS_V2-0.050
- P53_PATHWAY-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1215 | — | — | 0.886 |
| 2 | SRR6013563 | — | cohortMD2 | 0.874 |
| 3 | C3N-02087 | — | cohortA1 | 0.872 |
| 4 | TCGA-D8-A1JK-01A-11R-A13Q-07 | — | C | 0.866 |
| 5 | SRR934945 | — | — | 0.857 |
| 6 | SRR934924 | — | — | 0.854 |
| 7 | 957a7228-3558-48fd-81d9-13f951e0b597 | — | — | 0.853 |
| 8 | R242 | — | — | 0.853 |
| 9 | BS_KEA474HN | low-grade glioma | — | 0.852 |
| 10 | 82962 | EPN | Supratentorial EPN | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.440 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |